BIAF earnings analysis
What we found in BIAF's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Q2 2026 revenue was $1.511 million and diluted EPS was negative $0.64; the supplied quarterly history indicates revenue remained near the $1 million level seen in Q2 2025 and Q1 2026, while profitability remained deeply negative. The filing’s primary signal is liquidity stress: cash declined from $2.4 million at June 30, 2026 to $1.0 million on August 3, 2026, and management cited substantial doubt about continuing as a going concern for at least twelve months. A new Nasdaq deficiency notice dated July 30, 2026 further increases financing and trading risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Commercial revenue remains established
- The company reported approximately $2.9 million of revenue during the six months ended June 30, 2026, compared with $6.2 million during 2025, providing a specific measure of its commercial laboratory activity.
- Disclosure controls remain effective
- Management assessed disclosure controls and procedures as effective as of June 30, 2026, and reported no changes during the three months ended June 30, 2026 that could materially affect internal control over financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Severe liquidity and going-concern risk
- Cash and liquidity deteriorated materially: cash was $2.4 million as of June 30, 2026 but only $1.0 million as of August 3, 2026. Management stated that, without additional funding, resources were sufficient to continue operations only through August 2026 and identified substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
- Nasdaq minimum-bid-price deficiency
- The company disclosed a new Nasdaq listing risk after receiving notice on July 30, 2026 that its securities had closed below the $1.00 minimum bid price for 30 consecutive business days. Because of a prior 1-for-30 reverse stock split on September 19, 2025, the company was not eligible for the standard 180-calendar-day compliance period.
- Additional financing remains essential
- The company reported an accumulated deficit of $75.6 million as of June 30, 2026 and stated that it must raise additional capital through equity, debt, strategic relationships, grants, or other arrangements to support operations. Failure to obtain funding could require it to curtail or cease operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.64
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that, without additional funding, cash resources were expected to support operations through August 2026 and concluded there was substantial doubt about continuing as a going concern for at least twelve months.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- bioAffinity Technologies reported a Q1 2026 revenue of approximately $1.4 million, a decline of 27% year-over-year and a miss from the consensus estimate. While the company's CyPath® Lung unit sales surged 146%, overall…
- 10-K · March 16, 2026
- bioAffinity’s 2025 10-K shows the company actively refocusing toward its CyPath® Lung diagnostic: consolidated revenue fell ~34% to $6.2 million as management discontinued unprofitable pathology services, while CyPath®…
- 10-Q · November 14, 2025
- bioAffinity reported Q3 2025 revenue of $1,446,066 (down from $2,350,386 in Q3 2024) and a GAAP net loss of $5,051,084 (loss per share $(4.74)). The company materially strengthened its liquidity in Q3 via financing…
- 10-K · March 31, 2025
- bioAffinity’s 2024 results reflect a revenue inflection driven by the September 2023 acquisition of PPLS: consolidated revenue rose approximately 270% to $9.4 million for the year ended December 31, 2024. The company is…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BIAF makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever